Strategic Partnerships Opportunity: Leverage Samsung Bioepis established partnerships (Nipro in Japan; Regeneron/Bayer settlement for SB15) to expand co-developed biosimilars in key markets like Europe, Japan, and Asia-Pacific. Sales approach: propose joint commercialization agreements, local manufacturing collaborations, and regional access programs to accelerate market entry.

Europe Expansion Opportunity: Recent European launch of OPUVIZ 40 mg/mL aflibercept and ongoing ophthalmology biosimilar efforts indicate strong European market access potential. Sales play: identify ophthalmology clinics, hospital procurement channels, and payer pilots for anti-VEGF biosimilars to drive adoption.

Diversified Pipeline Opportunity: Broad biosimilar pipeline across immunology, oncology, ophthalmology, nephrology, endocrinology presents multiple cross-sell paths. Sales strategy: map unmet needs within these therapeutic areas and create a portfolio approach for regional health systems and biopharma partners seeking biosimilar adoption.

ObesityTherapy Opportunity: Collaboration with Epis NexLab and G2GBio on long-acting obesity treatments opens doors for future biosimilar or platform-based delivery solutions. Sales angle: position as a partner for translational research, regulatory support, and early-access programs in obesity care.

FinancialScale Opportunity: Reported revenue in the mid-to-high hundreds of millions with profitable margins; sizable global footprint implied by 1000+ employees and international launches. Sales focus: target large hospital groups, biopharma distributors, and regional contract manufacturing or licensing deals to unlock higher-volume biosimilar adoption and regional manufacturing partnerships.